A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Clinical trial NCT03447249 · COMPLETED
Trial details
- NCT number
- NCT03447249
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-07
- Primary completion
- 2019-02-05
- Enrollment
- 385
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.